These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

163 related items for PubMed ID: 20627189

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Mechanisms for the shuttling of plasma non-transferrin-bound iron (NTBI) onto deferoxamine by deferiprone.
    Evans P, Kayyali R, Hider RC, Eccleston J, Porter JB.
    Transl Res; 2010 Aug; 156(2):55-67. PubMed ID: 20627190
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Pharmacotherapy of iron overload in thalassaemic patients.
    Ceci A, Felisi M, De Sanctis V, De Mattia D.
    Expert Opin Pharmacother; 2003 Oct; 4(10):1763-74. PubMed ID: 14521486
    [Abstract] [Full Text] [Related]

  • 5. New chelation therapies and emerging chelating drugs for the treatment of iron overload.
    Kontoghiorghes GJ.
    Expert Opin Emerg Drugs; 2006 Mar; 11(1):1-5. PubMed ID: 16503822
    [Abstract] [Full Text] [Related]

  • 6. Effect of deferiprone or deferoxamine on right ventricular function in thalassemia major patients with myocardial iron overload.
    Smith GC, Alpendurada F, Carpenter JP, Alam MH, Berdoukas V, Karagiorga M, Ladis V, Piga A, Aessopos A, Gotsis ED, Tanner MA, Westwood MA, Galanello R, Roughton M, Pennell DJ.
    J Cardiovasc Magn Reson; 2011 Jul 06; 13(1):34. PubMed ID: 21733147
    [Abstract] [Full Text] [Related]

  • 7. Oral iron chelation therapy for thalassaemia: an uncertain scene.
    Pippard MJ, Weatherall DJ.
    Br J Haematol; 2000 Oct 06; 111(1):2-5. PubMed ID: 11091177
    [No Abstract] [Full Text] [Related]

  • 8. Transfusional iron overload and chelation therapy with deferoxamine and deferiprone (L1).
    Kontoghiorghes GJ, Pattichi K, Hadjigavriel M, Kolnagou A.
    Transfus Sci; 2000 Dec 06; 23(3):211-23. PubMed ID: 11099897
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Iron chelation with oral deferiprone in patients with thalassemia.
    Cohen AR, Martin MB.
    N Engl J Med; 1998 Dec 03; 339(23):1713-4. PubMed ID: 9867542
    [No Abstract] [Full Text] [Related]

  • 12. Adherence to desferrioxamine and deferiprone and the impact of deferiprone co-prescription in thalassaemia major patients. Does the addition of deferiprone improve adherence?
    Kidson-Gerber G, Lindeman R.
    Br J Haematol; 2008 Aug 03; 142(4):679-80. PubMed ID: 18537970
    [No Abstract] [Full Text] [Related]

  • 13. Advances in iron overload therapies. prospects for effective use of deferiprone (L1), deferoxamine, the new experimental chelators ICL670, GT56-252, L1NA11 and their combinations.
    Kontoghiorghes GJ, Eracleous E, Economides C, Kolnagou A.
    Curr Med Chem; 2005 Aug 03; 12(23):2663-81. PubMed ID: 16305464
    [Abstract] [Full Text] [Related]

  • 14. Comparison between deferoxamine and deferiprone (L1) in iron-loaded thalassemia patients.
    Taher A, Sheikh-Taha M, Koussa S, Inati A, Neeman R, Mourad F.
    Eur J Haematol; 2001 Jul 03; 67(1):30-4. PubMed ID: 11553264
    [Abstract] [Full Text] [Related]

  • 15. Improved survival in thalassemia major patients on switching from desferrioxamine to combined chelation therapy with desferrioxamine and deferiprone.
    Telfer PT, Warburton F, Christou S, Hadjigavriel M, Sitarou M, Kolnagou A, Angastiniotis M.
    Haematologica; 2009 Dec 03; 94(12):1777-8. PubMed ID: 19815834
    [No Abstract] [Full Text] [Related]

  • 16. Uses and limitations of serum ferritin, magnetic resonance imaging T2 and T2* in the diagnosis of iron overload and in the ferrikinetics of normalization of the iron stores in thalassemia using the International Committee on Chelation deferiprone/deferoxamine combination protocol.
    Kolnagou A, Yazman D, Economides C, Eracleous E, Kontoghiorghes GJ.
    Hemoglobin; 2009 Dec 03; 33(5):312-22. PubMed ID: 19814677
    [Abstract] [Full Text] [Related]

  • 17. Combined therapy with desferrioxamine and deferiprone in thalassemic patients: effect on urinary iron excretion.
    Kattamis A, Kassou C, Berdousi H, Ladis V, Papassotiriou I, Kattamis C.
    Haematologica; 2003 Dec 03; 88(12):1423-5. PubMed ID: 14687998
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Effect of transfusion on lipid peroxidation products in the plasma of thalassemic patients.
    Sher GD, Bartfay WJ, Liu PP, Lehotay DC.
    Transfusion; 1999 Mar 03; 39(3):333-4. PubMed ID: 10204599
    [No Abstract] [Full Text] [Related]

  • 20. Deferiprone approved for iron overload.
    Traynor K.
    Am J Health Syst Pharm; 2011 Nov 15; 68(22):2106. PubMed ID: 22058092
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.